{"id":4249,"date":"2017-12-25T14:42:49","date_gmt":"2017-12-25T13:42:49","guid":{"rendered":"http:\/\/wordpress.p545550.webspaceconfig.de\/uncategorized\/6-biotech-presse-lounge-meet-the-biotech-industry-at-the-izb\/"},"modified":"2020-07-15T12:13:42","modified_gmt":"2020-07-15T10:13:42","slug":"6-biotech-presse-lounge-meet-the-biotech-industry-at-the-izb","status":"publish","type":"post","link":"https:\/\/www.izb-online.de\/en\/6-biotech-presse-lounge-meet-the-biotech-industry-at-the-izb\/","title":{"rendered":"6. Biotech Press-Lounge: Meet the biotech industry at the IZB"},"content":{"rendered":"

[vc_row el_class=”gco-magazine-container”][vc_column el_class=”bildspalte”][vc_row_inner][vc_column_inner offset=”vc_col-lg-12 vc_col-md-12″][vc_column_text el_class=”gco-magazine–title”]<\/p>\n

6. Biotech Press-Lounge: Meet the biotech industry at the IZB<\/span><\/h1>\n

[\/vc_column_text][vc_column_text el_class=”gco-magazine–post-date”]December 2017[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”two-columns”][vc_column_inner][vc_single_image image=”4220″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 IZB[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription” el_id=”special-high”]Dr. Markus Dangl, Senior Vice President Research and Pre-Clinical Development, Medigene AG, Evelyn Warner, Chefredakteurin, LaBiotech.eu, Dr. Jens Altrichter, COO, Leukocare AG, Dr. Peter Hanns Zobel, CEO, F\u00f6rdergesellschaft IZB mbH, PhD. Paola Casarosa, Corporate Vice President Therapeutics, Boehringer Ingelheim (v.l.n.r.)[\/vc_column_text][vc_single_image image=”4232″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 IZB[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription” el_id=”special-high”]Alexandra Goller, Investor Relations, Morphosys AG, Claudia Gutjahr-L\u00f6ser, Managing Director, MC Services und Jochen Orlowski, Corporate Communications & Investor Relations, Morphosys AG (v.l.n.r.)[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy”][vc_column_inner][vc_column_text]Start-ups at the IZB are working in synchrony with medical progress
\n<\/strong><\/p>\n

The pharmaceutical, biotech and venture capital scene met up in the Biotech Press-Lounge to incubate new projects. On October 12, 2017 the Innovation and Start-Up Center for Biotechnology (IZB) hosted the sixth Biotech Press-Lounge at the Faculty Club G2B (Gateway to Biotech). With over 100 guests attending the event, every last place was taken. In his opening speech, Dr. Peter Hanns Zobel, Managing Director of the Innovation and Start-up Center for Biotechnology (IZB), stressed how \u00adimportant it is to bring together the players in the pharmaceutical, biotech and venture capital scene in an informal atmosphere, and also that he was delighted with the \u00adfinancing acquired at the IZB in 2017. Pieris AG, \u00adImmunic AG and Rigontec GmbH alone brought in deals amounting to \u00ad2 billion \u00adEuros. Current research was presented within the context of impulse talks. This time speakers at the Biotech Press-Lounge were Dr. Markus Dangl (Senior Vice President \u00adof Research and Pre-Clinical Development at Medigene AG), PhD. Paola Casarosa (Corporate Vice President of Therapeutics at Boehringer Ingelheim) and Dr. Jens Altrichter (COO of \u00adLeukocare AG). Evelyn Warner, chief editor of the portal Labiotech.eu, moderated the event.[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine–quote gco-magazine–quote-vertical-center”][vc_column_inner][vc_column_text]<\/p>\n

\"Portrait-Prof.-Dr.-Patrick-Baeuerle\"
\n\u00a9 IZB<\/span><\/div>\n
\n
\u201cA successful event: Dynamic format, highly interactive, great location!\u201d<\/h6>\n

Prof. Dr. Patrick Baeuerle
\nManaging Director
\nMPM Capital<\/p>\n<\/div>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy”][vc_column_inner][vc_column_text]Dr. Markus Dangl, Senior Vice President of Research and Pre-Clinical Development at Medigene AG, reported why neoantigens are currently a very exciting topic in the field of immunotherapy of tumor diseases, and how the technologies and know-how of Medigene can be used in the future to treat patients using highly effective, individualized cell therapies.
\n\u201cPartnerships play a strategic role in our research and development activities,\u201d said PhD. Paola Casarosa, Corporate Vice President of Therapeutics at Boehringer Ingelheim in her talk. \u201cThis is illustrated by the fact that 50 percent of our pipeline is based on external collaborations. We are looking for partnerships across the entire spectrum, from universities to biotech companies, to deliver value to patients,\u201d Casarosa explained.
\n[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”two-columns”][vc_column_inner][vc_single_image image=”4237″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 IZB[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription” el_id=”special-high”]PhD. Mick Cooper, Healthcare and Life Sciences Analyst, Trinity Delta, Dr. Robert Mayer, Senior Manager Public & IR, Medigene AG
\n(f.l.t.r.)[\/vc_column_text][vc_single_image image=”4239″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 IZB[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription” el_id=”special-high”]Dr. Jens Altrichter, COO, Leukocare AG and
\nSandra von Meier, Director Business Development, Merck Group (f.l.t.r.)[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine–quote”][vc_column_inner][vc_column_text]<\/p>\n

\u201cAn impressive event with an interesting audience and exciting presentations, which highlighted the strength of the biotech industry in Munich.\u201d<\/h6>\n

PhD. Mick Cooper
\nHealthcare and Life Sciences Analyst
\nTrinity Delta<\/p>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy” css=”.vc_custom_1591796511038{margin-top: 21px !important;}”][vc_column_inner][vc_column_text]Dr. Jens Altrichter, COO of Leukocare AG, outlined the increasing importance of advanced formulations in biopharmaceutical product development. \u201cBy taking into account formulation-relevant aspects already in the early phases of the development process, and using Leukocare\u2019s expertise and technology platform, our customers can achieve significant competitive advantages to exploit the maximum product and market potential in the future,\u201d as Altrichter explained the company\u2019s strategy.[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine–quote gco-magazine–quote-vertical-center” css=”.vc_custom_1594721209026{margin-bottom: 45px !important;}”][vc_column_inner][vc_column_text]<\/p>\n

\"Portrait-Dr.-Markus-Dangl\"
\n\u00a9 IZB<\/span><\/div>\n
\n
\u201cInteresting people, informative presentations, an excellent location and perfect organization, this event is highly recommendable.\u201c<\/h6>\n

Dr. Markus Dangl
\nSenior Vice President Research and Pre-Clinical Development, Medigene AG<\/p>\n<\/div>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner]\n\n

\n \n